Antibody‐Incorporated Nanomedicines for Cancer Therapy

Wu, Shun-Yu; Wu, Fugen; Chen, Xiaoyuan

doi:10.1002/adma.202109210

Cited by 42 publications

(25 citation statements)

References 647 publications

(1,029 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several strategies have been reported based on either full monoclonal antibody (full mAb−NPs) or antibody fragment conjugates (fragment−NPs). [14] This study presents a metaanalysis of literature data, seeking the identification of the optimal antibody moiety (full mAb or fragment)−NPs combination leading to the highest NP tumor uptake. The criteria for a rational selection were based on the material of the NPs (lipidic, polymeric, and organic/inorganic) with a particular emphasis on their size, their charge, the anti bodytargeting moieties (full mAb or fragment), the linker con jugation strategy, and the overall impact of these parameters on the pharmacokinetic and nonspecific biodistribution of these conjugates.…”

Section: Introductionmentioning

confidence: 99%

Optimal Physicochemical Properties of Antibody–Nanoparticle Conjugates for Improved Tumor Targeting

et al. 2022

View full text Add to dashboard Cite

Tumor‐targeted antibody (mAb)/fragment‐conjugated nanoparticles (NPs) represent an innovative strategy for improving the local delivery of small molecules. However, the physicochemical properties of full mAb–NPs and fragment–NPs—that is, NP material, size, charge, as well as the targeting antibody moiety, and the linker conjugation strategies—remain to be optimized to achieve an efficient tumor targeting. A meta‐analysis of 161 peer‐reviewed studies is presented, which describes the use of tumor‐targeted mAb–NPs and fragment−NPs from 2009 to 2021. The use of these targeted NPs is confirmed to result in significantly greater tumor uptake of NPs than that of naked NPs (7.9 ± 1.9% ID g−1 versus 3.2 ± 0.6% ID g−1, respectively). The study further demonstrates that for lipidic NPs, fragment–NPs provide a significantly higher tumor uptake than full mAb–NPs. In parallel, for both polymeric and organic/inorganic NPs, full mAb–NPs yield a significant higher tumor uptake than fragment–NPs. In addition, for both lipidic and polymeric NPs, the tumor uptake is improved with the smallest sizes of the conjugates. Finally, the pharmacokinetics of the conjugates are demonstrated to be driven by the NPs and not by the antibody moieties, independently of using full mAb–NPs or fragment–NPs, confirming the importance of optimizing the NP design to improve the tumor uptake.

show abstract

Section: Introductionmentioning

confidence: 99%

Optimal Physicochemical Properties of Antibody–Nanoparticle Conjugates for Improved Tumor Targeting

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Pharmacokinetic Study: Female 4T1 tumor-bearing Balb/c mice (20-25 g) were utilized to investigate the pharmaceutic profiles of LTX-SS-CA NPs. When tumors grew about 150 mm, [3] LTX solution (6 mg kg −1 ) and prodrug NPs (9 mg kg −1 ) were intravenously administrated into each group (n = 5). After the predetermined time points injection (2 min, 5 min, 20 min, 40 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h), the mice were executed and their blood, tumors, hearts, livers spleens, lungs, and kidneys were collected.…”

Section: Methodsmentioning

confidence: 99%

“…Regarding the temporal view, the maximum drug release in cancer cells is also expected when NPs accumulate in tumor tissues. Therefore, many strategies, such as antibodies modification [3] and sensitive chemical linkers, [4,5] have been applied to improve the efficiency of the spatiotemporal delivery of NPs. However, due to the complexity of the tumor microenvironment (TME), [6,7] ideal outcomes are difficult to achieve.…”

Section: Introductionmentioning

confidence: 99%

Glutathione Pulse Therapy: Promote Spatiotemporal Delivery of Reduction‐Sensitive Nanoparticles at the “Cellular Level” and Synergize PD‐1 Blockade Therapy

et al. 2022

View full text Add to dashboard Cite

Spatiotemporal delivery of nanoparticles (NPs) at the "cellular level" is critical for nanomedicine, which is expected to deliver as much cytotoxic drug into cancer cells as possible when NPs accumulate in tumors. However, macrophages and cancer-associated fibroblasts (CAFs) that are present within tumors limit the efficiency of spatiotemporal delivery. To overcome this limitation, glutathion pulse therapy is designed to promote reduction-sensitive Larotaxel (LTX) prodrug NPs to escape the phagocytosis of macrophages and penetrate through the stromal barrier established by CAFs in the murine triple negative breast cancer model. This therapy improves the penetration of NPs in tumor tissues as well as the accumulation of LTX in cancer cells, and remodels the immunosuppressive microenvironment to synergize PD-1 blockade therapy. More importantly, a method is established that can directly observe the biodistribution of NPs between different cells in vivo to accurately quantify the target drugs accumulated in these cells, thereby advancing the spatiotemporal delivery research of NPs at the "cellular level."

show abstract

“…Nanoparticles can be used as nanovehicles for specific targeting of tumor cells or tissues to overcome the issues of rapid plasma clearance, poor targeting ability, and systemic toxicity. Specific tumor-targeted drug delivery of antibody-coupled nanoparticles can be achieved by modifying suitable antibodies or their fragments, which are characterized by sophisticated selectivity, high recognition efficiency, and large diversity of antibodies [ 115 ]. In addition, the drug-to-antibody ratio of antibody-coupled nanoparticles can be easily adjusted and has a higher concentration of drug internalization than ADCs [ 115 ].…”

Section: Erbb2-targeted Treatments In Mcrcmentioning

confidence: 99%

“…Specific tumor-targeted drug delivery of antibody-coupled nanoparticles can be achieved by modifying suitable antibodies or their fragments, which are characterized by sophisticated selectivity, high recognition efficiency, and large diversity of antibodies [ 115 ]. In addition, the drug-to-antibody ratio of antibody-coupled nanoparticles can be easily adjusted and has a higher concentration of drug internalization than ADCs [ 115 ]. A study developed biodegradable antibody-coupled polymeric nanoparticles (NPs) using tamoxifen (Tam), poly (D, lactic-co-glycolic acid) (PLGA), and poly (vinyl alcohol-pyrrolidone) (PVP) coupled with Herceptin antibodies for targeted drug delivery and sustained release against breast cancer cells.…”

Section: Erbb2-targeted Treatments In Mcrcmentioning

confidence: 99%

Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies

Wang

Cao

et al. 2022

Cancers

View full text Add to dashboard Cite

Despite recent improvements in the comprehensive therapy of malignancy, metastatic colorectal cancer (mCRC) continues to have a poor prognosis. Notably, 5% of mCRC cases harbor Erb-B2 receptor tyrosine kinase 2 (ERBB2) alterations. ERBB2, commonly referred to as human epidermal growth factor receptor 2, is a member of the human epidermal growth factor receptor family of protein tyrosine kinases. In addition to being a recognized therapeutic target in the treatment of gastric and breast malignancies, it is considered crucial in the management of CRC. In this review, we describe the molecular biology of ERBB2 from the perspective of biomarkers for mCRC-targeted therapy, including receptor structures, signaling pathways, gene alterations, and their detection methods. We also discuss the relationship between ERBB2 aberrations and the underlying mechanisms of resistance to anti-EGFR therapy and immunotherapy tolerance in these patients with a focus on novel targeted therapeutics and ongoing clinical trials. This may aid the development of a new standard of care in patients with ERBB2-positive mCRC.

show abstract

Antibody‐Incorporated Nanomedicines for Cancer Therapy

Cited by 42 publications

References 647 publications

Optimal Physicochemical Properties of Antibody–Nanoparticle Conjugates for Improved Tumor Targeting

Optimal Physicochemical Properties of Antibody–Nanoparticle Conjugates for Improved Tumor Targeting

Glutathione Pulse Therapy: Promote Spatiotemporal Delivery of Reduction‐Sensitive Nanoparticles at the “Cellular Level” and Synergize PD‐1 Blockade Therapy

Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies

Contact Info

Product

Resources

About